Aug 14 (Reuters) - Acasti Pharma Inc ACST.V :
* ACASTI PHARMA PROVIDES BUSINESS UPDATE FOR THE FIRST QUARTER OF FISCAL 2019
* TRILOGY STUDIES SURPASS 50% ENROLLMENT AND CONTINUE ON TRACK TO COMPLETE ENROLLMENT IN 2018
* Q1 LOSS PER SHARE C$0.23
* ACASTI PHARMA - HAS "REASONABLE EXPECTATION" CO SHOULD BE ABLE TO RAISE MORE FUNDS LATER IN 2018 TO FINANCE TRILOGY PHASE 3 PROGRAM FOR CAPRE